Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]

NCT05536973 is registered in ClinicalTrials.gov with Adverum Biotechnologies, Inc. as lead sponsor.

NCT NCT05536973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05536973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
Lead sponsor
Adverum Biotechnologies, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 23, 2022
Completion date
August 31, 2028
Enrollment
69 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration